October 2016 Vol 9, No 7

As a parent and a faculty member at Thomas Jefferson University for the past 26 years (including 8 as Dean of our College of Population Health), I have been to more than my share of commencement exercises. Fortunately, I really like going to commencement. As a result, I was honored to be invited to address the 2016 graduating class of physician assistants from Philadelphia University, especially now that our 2 great centers of learning will be merging over the next 3 years.

The Affordable Care Act (ACA) initiated health insurance exchanges, or marketplaces, with health plans offering subsidies for plan members, to help individuals, families, and small businesses find health plans that fit their specific needs. By the end of the first open enrollment period, more than 8 million Americans selected qualified health plans through the ACA-initiated health insurance marketplace, and by February 2015, more than 10 million people enrolled and paid for health coverage through those plans in these marketplaces. Under state and federal rules and regulations, the ACA allowed insurers to offer a variety of well-defined health insurance plans and compete through the marketplace.

Health Plan Subsidies, Prescription Drugs, and Cost

The Centers for Disease Control and Prevention (CDC) estimates that approximately 29.1 million people in the United States have diagnosed (21 million) or undiagnosed (8.1 million) diabetes mellitus. The overall prevalence of diabetes in the US population is expected to increase as a result of growing rates of obesity and demographic shifts. Furthermore, the CDC estimates that even with a leveling of the incidence of diabetes, the prevalence of diabetes will double in the next 20 years, because of the aging US population. According to the CDC, the estimated total cost of diabetes in the United States in 2012 was $245 billion, including $176 billion for direct medical costs.

Provider and Payer Collaboration Needed to Ensure Adherence to Recommended Eye Examinations in Patients with Diabetes
Schizophrenia is a devastating psychiatric disorder with a global median lifetime prevalence of 4 per 1000 and a lifetime morbidity risk of 7.2 per 1000. The treatment of schizophrenia has been focused on eliminating the symptoms of the disease and has included antipsychotic medications since the 1950s.
Patient Characteristics, Adherence, and a Metric of Organizational Performance in Behavioral Health

Results 1 - 4 of 4
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • National Association of Specialty Pharmacy
  • Lynx CME